Ardea's Phase III Program For Promising Gout Drug Begins To Take Shape
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive efficacy and clean-as-whistle topline results for unpartnered RDEA594 leave some analysts predicting the drug could become a front-runner in the gout field.